综述:乙型肝炎相关肝细胞癌的预防
本文综述了乙型肝炎相关肝细胞癌的风险分层与三级预防策略。持续HBV感染与HCC存在病因学关联,未治疗的HBV患者存在男性、年龄增长、晚期肝纤维化、转氨酶持续升高、特定NTCP基因型、PM2.5暴露、HBeAg阳性、HBV基因型C/D/F、核心启动子突变比例高、前S缺失、高血清HBV DNA和HBsAg水平及合并HCV、HDV、HIV感染等显著风险因素。通过普遍HBV疫苗接种、高病毒载量母亲抗病毒预防、有效抗病毒治疗及治愈性治疗后抗病毒治疗,三级预防可降低全球HBV相关HCC负担。
要点
- 未治疗HBV患者的HCC显著风险因素包括男性、年龄增长、晚期肝纤维化、转氨酶持续升高及特定病毒和宿主因素。
- 普遍HBV疫苗接种和高病毒载量母亲的抗病毒预防可实现HBV相关HCC的一级预防。
- 有效抗病毒治疗可实现二级预防,降低慢性乙型肝炎患者HCC发生风险,但HCC是被预防还是被延迟值得进一步研究。
核心结论
- 通过三级预防策略,全球HBV相关HCC负担应随时间下降,甚至可随HBV治愈而消除。
研究设计与样本
- 综述:全面回顾近期发表于PubMed的研究,关键词包括慢性乙型肝炎、HBV、肝细胞癌、预防和抗病毒治疗。
主要发现
- HBV高流行区HCC发病率极高。
- 未治疗的HBV患者中,HCC显著风险因素包括男性、年龄增长、晚期肝纤维化、持续血清转氨酶升高、特定HBV进入受体(NTCP)基因型、PM2.5暴露、HBeAg阳性、HBV基因型C/D/F、核心启动子突变比例高、前S缺失、高血清HBV DNA和HBsAg水平及合并HCV、HDV和HIV感染。
- 普遍HBV疫苗接种和高病毒载量母亲的抗病毒预防可实现HBV相关HCC的一级预防。
- 有效抗病毒治疗降低慢性乙型肝炎患者HCC发生风险,已达到二级预防目标,但HCC是被预防还是被延迟值得进一步检查。
- 多项研究证实抗病毒治疗在治愈性治疗后降低HCC复发风险的三级预防效果。
关键数值与推荐
- 持续HBV感染与HCC存在病因学关联。
- 未治疗HBV患者的HCC显著风险因素包括男性、年龄增长、晚期肝纤维化、持续血清转氨酶升高、特定NTCP基因型、PM2.5暴露、HBeAg阳性、HBV基因型C/D/F、高比例核心启动子突变、前S缺失、高血清HBV DNA和HBsAg水平及合并HCV、HDV和HIV感染。
- 一级预防通过普遍HBV疫苗接种和高病毒载量母亲的抗病毒预防实现。
- 二级预防通过有效抗病毒治疗降低慢性乙型肝炎患者HCC发生风险实现。
- 三级预防通过抗病毒治疗降低治愈性治疗后HCC复发风险实现。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ample evidence indicates an aetiological association of persistent hepatitis B virus (HBV) infection with hepatocellular carcinoma (HCC). Several viral, host and external risk factors for the development of HBV-related HCC have been documented. AIMS: To summarise and discuss the risk stratification and the preventive strategies of HBV-related HCC. METHODS: Recent published studies identified from PubMed were comprehensively reviewed. The key words included chronic hepatitis B, HBV, hepatocellular carcinoma, prevention and antiviral therapy. RESULTS: The incidence of HCC is extremely high in HBV hyperendemic areas. For HBV patients left untreated, significant risk factors for HCC include male gender, aging, advanced hepatic fibrosis, persistent serum transaminase elevation, specific HBV entry receptor (NTCP) genotype, PM2.5 exposure, HBeAg positivity, HBV genotype C/D/F, high proportion of core promoter mutation, pre-S deletion, high serum levels of HBV DNA and HBsAg as well as co-infection with HCV, HDV and HIV. Primary prevention of HBV-related HCC can be achieved through universal HBV vaccination and anti-viral prophylaxis for high viraemic mothers. The goal of secondary prevention has been reached by effective anti-viral therapy to reduce the risk of HCC development in chronic hepatitis B patients. However, whether HCC is prevented or delayed deserves further examination. Finally, several studies confirmed the tertiary preventive effect of anti-viral therapy in reducing risk of HCC recurrence after curative therapies. CONCLUSIONS: Through the strategies of three-level prevention, the global burden of HBV-related HCC should decline over time and even be eliminated in conjunction with HBV cure.
引用
- Lin CL, Kao JH. Review article: the prevention of hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2018. PMID: 29722445. doi:10.1111/apt.14683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。